NCT07481383: A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer

Sponsor: Continuity Biosciences, LLC. Phase: PHASE1. Conditions: Pancreatic Adenocarcinoma Non-resectable